Tags: Misfolded%20proteins

blog

April 28, 2017

Trial of First Broad-Spectrum Drug for Neurodegeneration Seeking Volunteers

ADDF grantee Dr. Raymond Scott Turner is recruiting patients for a phase 2 trial of nilotinib—a leukemia drug being tested for treating Alzheimer’s.

announcements

April 20, 2017

ADDF-Funded Scientists Discover Two Repurposed Drugs With Promise for Alzheimer’s and FTD

A team of scientists from the Medical Research Council (MRC) in the UK have found two drugs, which block brain cell death and prevent neurodegeneration in preclinical studies. Their findings were published today in Brain.

announcements

March 7, 2017

$4 Million in New Grants Support Several First-in-Class Dementia Treatments

We recently awarded eight new grants totaling over $4 million to advance treatments for Alzheimer’s and related dementias. Several of the awards support new approaches to treating these diseases.

blog

February 15, 2017

Does Verubecestat Signal the End of the Amyloid Hypothesis?

Merck announces the end of another anti-amyloid drug trial, calling in to question the amyloid hypothesis and the fate of other anti-amyloid drugs.

blog

November 25, 2016

What Does the Failure of Solanezumab Mean?

Eli Lilly announced that its Alzheimer's drug solanezumab failed in its last phase 3 clinical trial. Howard Fillit, MD, discusses what this means, and where we go from here.

announcements

September 29, 2016

New Clinical Trial Will Test Cancer Drug as Alzheimer’s Treatment

Dr. Howard Fillit, the ADDF's Founding Executive Director and Chief Science Officer, says: "The ADDF is proud to support a clinical trial that holds such promise for Alzheimer's patients. This funding is part of our wider initiative to use the knowledge gained from cancer research to advance effective treatments for Alzheimer's."

announcements

September 27, 2016

Experimental Imaging Agent Reveals Concussion-Linked Brain Disease in Living Brain

Protein tracer shows distinctive pattern of brain protein deposition specific to this disease and typically confirmed after death

announcements

July 7, 2016

Five New Grants Fund Promising Treatments & Biomarkers

The ADDF awarded five new grants in May and June 2016, totaling nearly $1.5 million.

announcements

May 10, 2016

Ten New Grants Support Alzheimer’s Drug Discovery and Biomarker Development

The ADDF has awarded 10 new grants to researchers developing drugs for neurodegenerative diseases and biomarkers to detect their onset and progression.

announcements

April 9, 2015

Asceneuron Awarded Alzheimer’s Drug Discovery Foundation Grant

Asceneuron SA, an emerging leader in small molecule therapeutics targeting tauopathies for Alzheimer's and related neurodegenerative diseases, was awarded a $325,000 grant from the ADDF to support the development of its tau modulators.

blog

May 8, 2014

Understanding the Biology of Aging

Aging is the single greatest risk factor for Alzheimer’s disease. The challenge is translating this knowledge into a cure for the disease. 

announcements

June 12, 2013

ADDF Supports Madera Biosciences to Advance Small Molecule Drugs that Upregulate APOE

The ADDF announced that it has awarded follow-on funding to Madera Biosciences, Inc. to further develop its small molecule drugs designed to clear accumulated beta-amyloid from the brain.

announcements

February 5, 2013

Medicare Panel’s Failure to Recommend Payment for New Alzheimer’s Diagnostic Brain Imaging Scans

Howard Fillit, MD and George Vradenburg of USAgainstAlzheimer's issued a joint statement, responding to MEDCAC's opinion to not support Medicare reimbursement for PET amyloid imaging scans.

announcements

April 6, 2012

ADDF’s Seed Funding Leads to FDA Approval of Amyvid™, First Diagnostic Test for Alzheimer’s Disease

The FDA has approved Amyvid™, the first diagnostic test for Alzheimer's disease, for which the ADDF provided critical seed funding.